Novo Nordisk: Financial report for the period 1 January 2013 to 30 September 2013. Increased operating profit by 10% in the

Novo Nordisk: Financial report for the period 1 January 2013 to 30 September
2013. Increased operating profit by 10% in the first nine months of 2013

BAGSVAERD, Denmark, Oct. 31, 2013 (GLOBE NEWSWIRE) --

Sales growth of 8% driven by Victoza(®), Levemir(®) and NovoRapid(®)
Sales increased by 13% in local currencies and by 8% in Danish kroner to DKK
61.9 billion.

- Sales of modern insulins increased by 15% (10% in Danish kroner).
- Sales of Victoza(®) increased by 28% (24% in Danish kroner).
- Sales in North America increased by 20% (17% in Danish kroner).
- Sales in International Operations increased by 15% (8% in Danish kroner).




Company announcement No 68 / 2013: http://hugin.info/2013/R/1739405/583808.pdf

[HUG#1739405]


CONTACT: CONTACTS FOR FURTHER INFORMATION
         Media:
         Mike Rulis +45 4442 3573
         mike@novonordisk.com

         Ken Inchausti (US) +1 609 514 8316
         kiau@novonordisk.com
        
         Investors:
         Kasper Roseeuw Poulsen +45 3079 4303
         krop@novonordisk.com

         Frank Daniel Mersebach +45 3079 0604
         fdni@novonordisk.com

         Lars Borup Jacobsen +45 3075 3479
         lbpj@novonordisk.com

         Daniel Bohsen +45 3079 6376
         dabo@novonordisk.com

         Jannick Lindegaard (US) +1 609 786 4575
         jlis@novonordisk.com